A review of the research progress on tumor-associated macrophages

doi:10.11958/20241415

Abstract

Abstract:

In the tumor microenvironment, tumor-associated macrophages construct complex interaction networks through highly plasticity, promoting the dynamic evolution of the cancer ecosystem. With the innovation of single-cell sequencing technology, the heterogeneity, functional diversity, and interaction mechanisms of tumor-associated macrophages with tumor microenvironment have been revealed. This suggests that tumor-associated macrophages may become a new target for tumor targeted therapy, driving the development of precision anti-cancer strategies. This review summarizes the relevant research progress, explores the interaction mechanisms, describes the classification and clinical therapeutic potential, aiming to provide new perspectives and guidance for tumor research and clinical practice.

Key words: tumor-associated macrophages, tumor microenvironment, myeloid cells, RNA-Seq, cell communication

CLC Number:

R730.3

References 40

[1]	KLOOSTERMAN D J, AKKARI L. Macrophages at the interface of the co-evolving cancer ecosystem[J]. Cell, 2023, 186(8):1627-1651. doi:10.1016/j.cell.2023.02.020.
[2]	CHRISTOFIDES A, STRAUSS L, YEO A, et al. The complex role of tumor-infiltrating macrophages[J]. Nat Immunol, 2022, 23(8):1148-1156. doi:10.1038/s41590-022-01267-2.
[3]	CASSETTA L, POLLARD J W. A timeline of tumour-associated macrophage biology[J]. Nat Rev Cancer, 2023, 23(4):238-257. doi:10.1038/s41568-022-00547-1.
[4]	EVANS R, ALEXANDER P. Cooperation of immune lymphoid cells with macrophages in tumour immunity[J]. Nature, 1970, 228(5272):620-622. doi:10.1038/228620a0.
[5]	BISWAS S K, ALLAVENA P, MANTOVANI A. Tumor-associated macrophages:functional diversity, clinical significance,and open questions[J]. Semin Immunopathol, 2013, 35(5):585-600. doi:10.1007/s00281-013-0367-7.
[6]	MANTOVANI A, SICA A, SOZZANI S, et al. The chemokine system in diverse forms of macrophage activation and polarization[J]. Trends Immunol, 2004, 25(12):677-686. doi:10.1016/j.it.2004.09.015.
[7]	MURRAY P J, ALLEN J E, BISWAS S K, et al. Macrophage activation and polarization:nomenclature and experimental guidelines[J]. Immunity, 2014, 41(1):14-20. doi:10.1016/j.immuni.2014.06.008.
[8]	YANG M, MCKAY D, POLLARD J W, et al. Diverse functions of macrophages in different tumor microenvironments[J]. Cancer Res, 2018, 78(19):5492-5503. doi:10.1158/0008-5472.CAN-18-1367.
[9]	QIAN Y, YIN Y, ZHENG X, et al. Metabolic regulation of tumor-associated macrophage heterogeneity:insights into the tumor microenvironment and immunotherapeutic opportunities[J]. Biomark Res, 2024, 12(1):1. doi:10.1186/s40364-023-00549-7.
[10]	CHE L H, LIU J W, HUO J P, et al. A single-cell atlas of liver metastases of colorectal cancer reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy[J]. Cell Discov, 2021, 7(1):80. doi:10.1038/s41421-021-00312-y.
[11]	CHENG S, LI Z, GAO R, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells[J]. Cell, 2021, 184(3):792-809.e23. doi:10.1016/j.cell.2021.01.010.
[12]	MA R Y, BLACK A, QIAN B Z. Macrophage diversity in cancer revisited in the era of single-cell omics[J]. Trends Immunol, 2022, 43(7):546-563. doi:10.1016/j.it.2022.04.008.
[13]	BILL R, WIRAPATI P, MESSEMAKER M, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers[J]. Science, 2023, 381(6657):515-524. doi:10.1126/science.ade2292.
[14]	TAURIELLO D, BATLLE E. Targeting the microenvironment in advanced colorectal cancer[J]. Trends Cancer, 2016, 2(9):495-504. doi:10.1016/j.trecan.2016.08.001.
[15]	MOCHIZUKI S, AO T, SUGIURA T, et al. Expression and function of a disintegrin and metalloproteinases in cancer-associated fibroblasts of colorectal cancer[J]. Digestion, 2020, 101(1):18-24. doi:10.1159/000504087.
[16]	KRISHNAN V, CHONG Y L, TAN T Z, et al. TGFβ promotes genomic instability after loss of RUNX3[J]. Cancer Res, 2018, 78(1):88-102. doi:10.1158/0008-5472.CAN-17-1178.
[17]	ZHANG R, QI F, ZHAO F, et al. Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer[J]. Cell Death Dis, 2019, 10(4):273. doi:10.1038/s41419-019-1435-2.
[18]	ZHOU W, GUO S, LIU M, et al. Targeting CXCL12/CXCR4 axis in tumor immunotherapy[J]. Curr Med Chem, 2019, 26(17):3026-3041. doi:10.2174/0929867324666170830111531.
[19]	CHO H, SEO Y, LOKE K M, et al. Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion[J]. Clin Cancer Res, 2018, 24(21):5407-5421. doi:10.1158/1078-0432.CCR-18-0125.
[20]	CASANOVA-ACEBES M, DALLA E, LEADER A M, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells[J]. Nature, 2021, 595(7868):578-584. doi:10.1038/s41586-021-03651-8.
[21]	ENGBLOM C, PFIRSCHKE C, PITTET M J. The role of myeloid cells in cancer therapies[J]. Nat Rev Cancer, 2016, 16(7):447-462. doi:10.1038/nrc.2016.54.
[22]	秦雅含, 张珂, 张梦雨, 等. MDSC靶向免疫治疗胰腺癌的研究进展[J]. 上海交通大学学报(医学版), 2023, 43(10):1317-1323.
	QIN Y H, ZAHGN K, ZHANG M Y, et al. Research progress of MDSCs-targeted immunotherapy for pancreatic cancer[J]. Journal of Shanghai Jiaotong University(Medical Science), 2023, 43(10):1317-1323. doi:10.3969/j.issn.1674-8115.2023.10.014.
[23]	GERHARD G M, BILL R, MESSEMAKER M, et al. Tumor-infiltrating dendritic cell states are conserved across solid human cancers[J]. J Exp Med, 2021, 218(1):e20200264. doi:10.1084/jem.20200264.
[24]	WU J, LU A D, ZHANG L P, et al. Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2019, 40(1):52-57. doi:10.3760/cma.j.issn.0253-2727.2019.01.010.
[25]	SIWICKI M, PITTET M J. Versatile neutrophil functions in cancer[J]. Semin Immunol, 2021,57:101538. doi:10.1016/j.smim.2021.101538.
[26]	MANTOVANI A, ALLAVENA P, MARCHESI F, et al. Macrophages as tools and targets in cancer therapy[J]. Nat Rev Drug Discov, 2022, 21(11):799-820. doi:10.1038/s41573-022-00520-5.
[27]	BEJARANO L, JORDĀO M, JOYCE J A. Therapeutic targeting of the tumor microenvironment[J]. Cancer Discov, 2021, 11(4):933-959. doi:10.1158/2159-8290.CD-20-1808.
[28]	PITTET M J, MICHIELIN O, MIGLIORINI D. Clinical relevance of tumour-associated macrophages[J]. Nat Rev Clin Oncol, 2022, 19(6):402-421. doi:10.1038/s41571-022-00620-6.
[29]	JING L, AN Y, CAI T, et al. A subpopulation of CD146⁺ macrophages enhances antitumor immunity by activating the NLRP3 inflammasome[J]. Cell Mol Immunol, 2023, 20(8):908-923. doi:10.1038/s41423-023-01047-4.
[30]	WANG X, XU Y, SUN Q, et al. New insights from the single-cell level:tumor associated macrophages heterogeneity and personalized therapy[J]. Biomed Pharmacother, 2022,153:113343. doi:10.1016/j.biopha.2022.113343.
[31]	XIANG X, WANG J, LU D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy[J]. Signal Transduct Target Ther, 2021, 6(1):75. doi:10.1038/s41392-021-00484-9.
[32]	CASSIER P A, ITALIANO A, GOMEZ-ROCA C A, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue:a dose-escalation and dose-expansion phase 1 study[J]. Lancet Oncol, 2015, 16(8):949-956. doi:10.1016/S1470-2045(15)00132-1.
[33]	NYWENING T M, WANG-GILLAM A, SANFORD D E, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer:a single-centre, open-label,dose-finding,non-randomised,phase 1b trial[J]. Lancet Oncol, 2016, 17(5):651-662. doi:10.1016/S1470-2045(16)00078-4.
[34]	JIAO X, VELASCO-VELÁZQUEZ M A, WANG M, et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion[J]. Cancer Res, 2018, 78(7):1657-1671. doi:10.1158/0008-5472.CAN-17-0915.
[35]	HALAMA N, ZOERNIG I, BERTHEL A, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients[J]. Cancer Cell, 2016, 29(4):587-601. doi:10.1016/j.ccell.2016.03.005.
[36]	LIU J, WANG C, MA X, et al. High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFβ1[J]. J Pathol, 2019, 247(4):481-493. doi:10.1002/path.5207.
[37]	HUGHES R, QIAN B Z, ROWAN C, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy[J]. Cancer Res, 2015, 75(17):3479-3491. doi:10.1158/0008-5472.CAN-14-3587.
[38]	GUO F, WANG Y, LIU J, et al. CXCL12/CXCR4:a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks[J]. Oncogene, 2016, 35(7):816-826. doi:10.1038/onc.2015.139.
[39]	WEISKOPF K, RING A M, HO C C, et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies[J]. Science, 2013, 341(6141):88-91. doi:10.1126/science.1238856.
[40]	DECZKOWSKA A, WEINER A, AMIT I. The physiology,pathology,and potential therapeutic applications of the TREM2 signaling pathway[J]. Cell, 2020, 181(6):1207-1217. doi:10.1016/j.cell.2020.05.003.